» Articles » PMID: 21810243

Temporal Changes in HCV Genotype Distribution in Three Different High Risk Populations in San Francisco, California

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2011 Aug 4
PMID 21810243
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatitis C virus (HCV) genotype (GT) has become an important measure in the diagnosis and monitoring of HCV infection treatment. In the United States (U.S.) HCV GT 1 is reported as the most common infecting GT among chronically infected patients. In Europe, however, recent studies have suggested that the epidemiology of HCV GTs is changing.

Methods: We assessed HCV GT distribution in 460 patients from three HCV-infected high risk populations in San Francisco, and examined patterns by birth cohort to assess temporal trends. Multiple logistic regression was used to assess factors independently associated with GT 1 infection compared to other GTs (2, 3, and 4).

Results: Overall, GT 1 was predominant (72.4%), however younger injection drug users (IDU) had a lower proportion of GT 1 infections (54.7%) compared to older IDU and HIV-infected patients (80.5% and 76.6%, respectively). Analysis by birth cohort showed increasing proportions of non-GT 1 infections associated with year of birth: birth before 1970 was independently associated with higher adjusted odds of GT 1: AOR 2.03 (95% CI: 1.23, 3.34). African-Americans as compared to whites also had higher adjusted odds of GT 1 infection (AOR: 3.37; 95% CI: 1.89, 5.99).

Conclusions: Although, HCV GT 1 remains the most prevalent GT, especially among older groups, changes in GT distribution could have significant implications for how HCV might be controlled on a population level and treated on an individual level.

Citing Articles

Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.

Taherkhani R, Farshadpour F World J Hepatol. 2018; 9(33):1239-1252.

PMID: 29312527 PMC: 5745585. DOI: 10.4254/wjh.v9.i33.1239.


Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.

Assoumou S, Tasillo A, Leff J, Schackman B, Drainoni M, Horsburgh C Clin Infect Dis. 2017; 66(3):376-384.

PMID: 29020317 PMC: 5848253. DOI: 10.1093/cid/cix798.


Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States.

Gordon S, Trudeau S, Li J, Zhou Y, Rupp L, Holmberg S J Clin Gastroenterol. 2017; 53(1):40-50.

PMID: 28737649 PMC: 5776051. DOI: 10.1097/MCG.0000000000000872.


The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Linas B, Barter D, Morgan J, Pho M, Leff J, Schackman B Ann Intern Med. 2015; 162(9):619-29.

PMID: 25820703 PMC: 4420667. DOI: 10.7326/M14-1313.


Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Cunningham E, Applegate T, Lloyd A, Dore G, Grebely J Nat Rev Gastroenterol Hepatol. 2015; 12(4):218-30.

PMID: 25782091 DOI: 10.1038/nrgastro.2015.36.


References
1.
Strickland G, El-Kamary S, Klenerman P, Nicosia A . Hepatitis C vaccine: supply and demand. Lancet Infect Dis. 2008; 8(6):379-86. DOI: 10.1016/S1473-3099(08)70126-9. View

2.
Schroter M, Zollner B, Schafer P, Reimer A, Muller M, Laufs R . Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol. 2002; 40(5):1866-8. PMC: 130918. DOI: 10.1128/JCM.40.5.1866-1868.2002. View

3.
Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-33. PMC: 3466592. DOI: 10.1086/524143. View

4.
Bourliere M, Barberin J, Rotily M, Guagliardo V, Portal I, Lecomte L . Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat. 2002; 9(1):62-70. DOI: 10.1046/j.1365-2893.2002.00319.x. View

5.
Hepburn M, Hepburn L, Cantu N, Lapeer M, Lawitz E . Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med. 2004; 117(3):163-8. DOI: 10.1016/j.amjmed.2004.02.043. View